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Induction of Ca2+ release from isolated, preloaded rat heart mitochondria by low concentrations (< 5 PM) of adriamycin 
aglycones, has recently been reported [(1988) Biochem. Pharmacol. 37, 803). Ca*+ release occurs via a generalized, CaZ+ -
dependent increase in the permeability of the inner mitochondrial membrane to small molecules. The process is antago- 
nized by dithiothreitol, suggesting thiol involvement. This communication demonstrates modification of mitochondrial 
sulthydryl groups, detected as decreased 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) reactivity, by adriamycin aglycones. 
Ca2+ release and sulthydryl modification are shown to depend similarly on aglycone concentration and on the C-7 substi- 
tuent of the anthracycline ring. In addition, DTNB elicits Ca2+ release. It can therefore be proposed that adriamycin 
aglycones alter mitochondrial membrane permeability by altering mitochondrial thiol status. 
Adriamycin; Mitochondria; Sulfhydryl group; Ca*+: Membrane permeability; (Rat heart) 
1. INTRODUCTION 
Adriamycin (Doxorubicin) is a potent an- 
tineoplastic agent [1,2], but its therapeutic 
usefulness is limited by cumulative and irreversible 
cardiotoxicity [ 3,4]. Several biochemical mecha- 
nisms have been proposed to account for the toxic 
effects of the drug (review [5]). Perhaps foremost 
among them are schemes (e.g. [6]) involving redox 
reactions of the anthraquinone ring, leading in 
turn to adriamycin-free radicals, activated oxygen 
species, and lipid peroxidation. None of these 
hypothetical mechanisms has been unequivocally 
confirmed. Most importantly, peroxidation of car- 
diac lipids is not always a consequence of 
adriamycin exposure [7,8]. 
This laboratory has recently reported that low 
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concentrations (< 5 PM) of aglycone metabolites 
of adriamycin trigger the release of Ca’+ from 
isolated, preloaded rat heart mitochondria [9]. 
Aglycone-induced Ca2+ release is independent of 
Na+ and is accompanied by oxidation of pyridine 
nucleotides, membrane potential collapse, 
mitochondrial swelling, and a transition of the 
mitochondria from the condensed to the orthodox 
configuration. Ca2+ release is inhibited by 
dithiothreitol and ATP. These properties are suffi- 
cient to demonstrate that aglycone-induced Ca2+ 
release is representative of a previously identified 
phenomenon, namely, a generalized, Ca2+- 
dependent increase of inner membrane permeabili- 
ty to small (< 1000 daltons) solutes [lO,ll]. 
This communication demonstrates that 
adriamycin aglycones modify mitochondrial 
sulfhydryl groups. Sulfhydryls have been im- 
plicated in maintenance of inner membrane 
permeability properties [ 12,131. It can therefore be 
proposed that the aglycones elicit Ca2+ release by 
altering mitochondrial thiol status. Consistent with 
this proposal, CaZf release and sulfhydryl 
modification are found to depend similarly on 
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aglycone concentration and on the C-7 substituent 
on the anthracycline ring. 
2. MATERIALS AND METHODS 
Mitochondria were isolated from the hearts of male Sprague- 
Dawley rats by a modification [9] of the procedure of Sordahl 
[14] which yields a mixed population of interfibrillar and sub- 
sarcolemmal organelles. All measurements were carried out in 
a standard resin (Chelex-lOO)-treated buffer consisting of 
sucrose, 100 mM; KCl, 50 mM; Mops-KOH, pH 7.2, 20 mM; 
and KHzPO+ 1.7 mM to which was added 0.8 pM rotenone 
and mitochondrial protein equivalent to 0.2 mg/ml. 
Temperature was maintained at 30°C. 
Ca’+ uptake and release were followed by means of a 
Ca*+-selective electrode (Radiometer F2112Ca, K8040 
reference). Mitochondrial sulfhydryl groups were measured us- 
ing IOOpM 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) [15]. 
Production of the nitrothiobenzoate anion was followed at the 
wavelength pair 520-412 nm [16] in an SLM-Aminco DW-2000 
spectrophotometer and quantitated using a differential extinc- 
tion coefficient of 1.15 x 10m4 M-’ determined by calibration 
with cysteine. All data shown are representative of multiple ex- 
periments. Protein was determined as in [17]. 
The 7-hydroxy and 7-deoxy aglycones of adriamycin were 
prepared, as described [9], according to Bachur [18] and Smith 
et al. 1191. Adriamycin hydrochloride was generously supplied 
by Adria Laboratories, Columbus, OH. Sucrose, Mops, cys- 
teine, NADH, DTNB, rotenone, and succinate were purchased 
from Sigma. Chelex 100 was obtained from Bio-Rad (Rich- 
mond, CA) and NADH dehydrogenase from Boehringer 
Mannheim (Indianapolis, IN). All other reagents were of the 
highest quality available. 
3. RESULTS 
The time course of the reaction of the thiol- 
specific reagent DTNB (100pM) with the 
sulfhydryl groups of isolated rat heart mitochon- 
dria is shown in fig. 1. In 11 experiments, the probe 
reacted with 37.4 + 2.9 nmol/mg protein over a 
period of 30 min. This agrees well with the value of 
39.8 f 3.0 reported for pig heart mitochondria 
[20]. The slow time course is consistent with prior 
interpretation of the DTNB reaction as an in- 
dicator of protein thiols [ 161. 
In the presence of the 7-hydroxy aglycone of 
adriamycin (17.3 FM), sulfhydryl detection was 
markedly reduced (fig.1). An average of only 
17.6 f 2.1 nmol/mg (n = 11) sulfhydryls reacted 
with the probe, under these conditions, in 30 min, 
corresponding to a 52.6 f 6.5% decrease in 
sulfhydryl reactivity. This effect is significant at 
the P +O.OOl level (Student’s t-test). Mitochon- 
drial sulfhydryl reactivity was never completely 
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Fig.1. Effect of ‘I-hydroxy adriamycin aglycone on 
mitochondrial sulfhydryl group detection by DTNB. 
Mitochondria were added to standard buffer supplemented 
with rotenone, 5 mM succinate, 1OOpM DTNB, and either 
17.3 pM aglycone or an equivalent volume of the solvent 
dimethylsulfoxide. 
eliminated by adriamycin aglycone. Experiments 
in which inhibition was enhanced either by increas- 
ing aglycone concentration or by decreasing DTNB 
concentration suggested maximal inhibition of 
65%. Inhibition of the DTNB reaction occurred 
with a lag of 3-6 min (fig.1). The lag was not 
altered by incubation of the mitochondria with 
aglycone for 5 min prior to the addition of DTNB. 
The lag therefore reflects interaction of aglycone 
with thiol groups which are relatively inaccessible 
to DTNB and not the time course of aglycone 
action. 
Several observations indicate that adriamycin 
aglycone chemically alters mitochondrial sul- 
fhydryls rather than simply decreasing probe ac- 
cess. (i) Aglycone effects were partially overcome 
by increasing the DTNB concentration. At 2 mM 
DTNB, 17.3 ,KM aglycone inhibited sulfhydryl 
group detection only 34%. (ii) Addition of Triton 
X-100 (0.16%) after 30 min increased by 53% the 
number of sulfhydryl groups detected by DTNB 
but failed to overcome inhibition by the aglycone. 
(iii) In mitochondria, adriamycin is reduced by 
NADH dehydrogenase [21]. In a model system 
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Fig.2. Effect of adriamycin and its aglycone metabolites on 
mitochondrial sulfhydryl group detection by DTNB. 
Measurements were conducted as shown in fig. 1. 
consisting of cysteine, NADH, and NADH 
dehydrogenase, where probe access is not an issue, 
pre-incubation with adriamycin or with the 
7-hydroxy aglycone decreased the subsequent reac- 
tion of cysteine with 1OOpM DTNB. 
Ca’+ release from isolated rat heart mitochon- 
dria is difficult to quantitate but is clearly seen at 
5 PM hydroxy aglycone. Furthermore, both the 
7-hydroxy and 7-deoxy aglycones are potent releas- 
ing agents whereas the parent molecule is ineffec- 
tive [9]. Mitochondrial sulfhydryl groups 
responded similarly (fig.2). Inhibition of 
sulfhydryl group detection by DTNB was evident 
at l-2 PM aglycone and was half-maximal at 
1.7 PM and 4.5 PM 7-deoxy and 7-hydroxy 
aglycone, respectively. In contrast, >20 PM 
adriamycin had little effect on mitochondrial 
thiols. 
If aglycone-induced Ca*+ release can be at- 
tributed to modification of DTNB-reactive thiol 
groups, then DTNB itself should also induce Ca2+ 
release. This is indeed the case (fig.3). IOOpM 
DTNB and 17.3 yM hydroxy aglycone are similar- 
ly potent releasing agents. 
4. DISCUSSION 
The data summarized above suggest that 
adriamycin aglycones modify mitochondrial 
sulfhydryl groups and in so doing induce an in- 
crease in inner membrane permeability which can 
be observed as Ca*+ release. Sulfhydryl modifica- 
tion, either oxidation or arylation and either direct 
or mediated by activated oxygen species [22], is a 
logical chemical consequence of generation of the 
aglycone-free radical. It can therefore be suggested 
that the critical event in adriamycin cardiotoxicity 
is loss of subcellular compartmentation resulting 
not from lipid peroxidation but from modification 
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Fig.3. Effect of DTNB and 7-hydroxy adriamycin aglycone on Ca*’ retention by isolated, preloaded rat heart mitochondria. 
Mitochondria (0.4 mg protein) were preincubated for 3 min in 2 ml standard buffer supplemented with rotenone. At the points 
indicated, Ca”+ (60 nmol), succinate (5 mM), and either 17.3 ,zM aglycone (trace 1) or 100pM DTNB (trace 2) were added. Traces 
3 and 4 are solvent controls for the aglycone and DTNB, respectively. 
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of mitochondrial thiols. This is consistent with the 
report that sulfhydryl-containing reagents, in some 
instances, reduce anthracycline cardiotoxicity [23]. 
Sulfhydryl modification is induced in this system 
by 7-hydroxy adriamycin aglycone. The 7-deoxy 
compound, which is physiologically more impor- 
tant [24], is also more potent. Adriamycin itself is 
without marked effect in this system. Enhanced 
potency of the more hydrophobic aglycones may 
reflect increased access to key membrane thiols. 
Recent reports have identified 7-deoxy adriamycin 
aglycone as a major metabolite in rat hearts [25], 
in aerobic rat hepatocytes [26] and in some humans 
[27] after adriamycin exposure. 
Adriamycin elicits Ca*+ release from sar- 
coplasmic reticulum [28], and sulfhydryl reagents 
have also been found to alter Ca2+ sequestration 
by liver microsomes [16] and by vesicles of both 
liver plasma membrane [29] and skeletal muscle 
sarcoplasmic reticulum [30-321. In the latter case, 
as in mitochondria, a generalized permeability in- 
crease is induced [30]. Alteration of the 
permeability of cellular membranes mediated by 
thiol modification may thus represent a general 
mechanism of adriamycin toxicity, with the 
relative effectiveness of the parent compound and 
various metabolites on any particular membrane 
system governed by their access to membrane 
sulfhydryls. 
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